245 related articles for article (PubMed ID: 36702900)
61. Highly Efficient and Versatile Plasmid-Based Gene Editing in Primary T Cells.
Kornete M; Marone R; Jeker LT
J Immunol; 2018 Apr; 200(7):2489-2501. PubMed ID: 29445007
[TBL] [Abstract][Full Text] [Related]
62. Enhanced Genome Editing Tools For Multi-Gene Deletion Knock-Out Approaches Using Paired CRISPR sgRNAs in CHO Cells.
Schmieder V; Bydlinski N; Strasser R; Baumann M; Kildegaard HF; Jadhav V; Borth N
Biotechnol J; 2018 Mar; 13(3):e1700211. PubMed ID: 28976642
[TBL] [Abstract][Full Text] [Related]
63. Versatile and multifaceted CRISPR/Cas gene editing tool for plant research.
Pandey PK; Quilichini TD; Vaid N; Gao P; Xiang D; Datla R
Semin Cell Dev Biol; 2019 Dec; 96():107-114. PubMed ID: 31022459
[TBL] [Abstract][Full Text] [Related]
64. Elimination of HIV-1 Genomes from Human T-lymphoid Cells by CRISPR/Cas9 Gene Editing.
Kaminski R; Chen Y; Fischer T; Tedaldi E; Napoli A; Zhang Y; Karn J; Hu W; Khalili K
Sci Rep; 2016 Mar; 6():22555. PubMed ID: 26939770
[TBL] [Abstract][Full Text] [Related]
65. Optical Control of a CRISPR/Cas9 System for Gene Editing by Using Photolabile crRNA.
Zhang Y; Ling X; Su X; Zhang S; Wang J; Zhang P; Feng W; Zhu YY; Liu T; Tang X
Angew Chem Int Ed Engl; 2020 Nov; 59(47):20895-20899. PubMed ID: 33448579
[TBL] [Abstract][Full Text] [Related]
66. Massively parallel base editing screens to map variant effects on anti-tumor hallmarks of primary human T cells.
Walsh ZH; Shah P; Kothapalli N; Nikolenyi G; Shah SB; Leuzzi G; Mu M; Ho P; Abuzaid S; Brodtman ZD; Vasan N; AlQuraishi M; Milner JD; Ciccia A; Melms JC; Izar B
bioRxiv; 2023 Dec; ():. PubMed ID: 38168306
[TBL] [Abstract][Full Text] [Related]
67. CAR T therapy beyond cancer: the evolution of a living drug.
Baker DJ; Arany Z; Baur JA; Epstein JA; June CH
Nature; 2023 Jul; 619(7971):707-715. PubMed ID: 37495877
[TBL] [Abstract][Full Text] [Related]
68. Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity.
Ma L; Hostetler A; Morgan DM; Maiorino L; Sulkaj I; Whittaker CA; Neeser A; Pires IS; Yousefpour P; Gregory J; Qureshi K; Dye J; Abraham W; Suh H; Li N; Love JC; Irvine DJ
Cell; 2023 Jul; 186(15):3148-3165.e20. PubMed ID: 37413990
[TBL] [Abstract][Full Text] [Related]
69. CLASH: large-scale engineering system for the discovery of better CAR T cells.
Dai X
Nat Rev Immunol; 2023 Sep; 23(9):541. PubMed ID: 37344683
[No Abstract] [Full Text] [Related]
70. Self-assembled nanoparticles: A new platform for revolutionizing therapeutic cancer vaccines.
Shi T; Sun M; Lu C; Meng F
Front Immunol; 2023; 14():1125253. PubMed ID: 36895553
[TBL] [Abstract][Full Text] [Related]
71. Enhancement of the viability of T cells electroporated with DNA via osmotic dampening of the DNA-sensing cGAS-STING pathway.
An J; Zhang CP; Qiu HY; Zhang HX; Chen QB; Zhang YM; Lei XL; Zhang CX; Yin H; Zhang Y
Nat Biomed Eng; 2024 Feb; 8(2):149-164. PubMed ID: 37500747
[TBL] [Abstract][Full Text] [Related]
72. Engineering enhanced chimeric antigen receptor-T cell therapy for solid tumors.
Neeser A; Ramasubramanian R; Wang C; Ma L
Immunooncol Technol; 2023 Sep; 19():100385. PubMed ID: 37483659
[TBL] [Abstract][Full Text] [Related]
73. Development of novel self-assembled vaccines based on tumour-specific antigenic peptide and TLR2 agonist for effective breast cancer immunotherapy via activating CD8
Shi W; Tong Z; Chen S; Qiu Q; Zhou J; Qian H
Immunology; 2023 Aug; 169(4):454-466. PubMed ID: 36946150
[TBL] [Abstract][Full Text] [Related]
74. Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice.
Dong X; Ren J; Amoozgar Z; Lee S; Datta M; Roberge S; Duquette M; Fukumura D; Jain RK
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36898734
[TBL] [Abstract][Full Text] [Related]
75. CAR immune cells: design principles, resistance and the next generation.
Labanieh L; Mackall CL
Nature; 2023 Feb; 614(7949):635-648. PubMed ID: 36813894
[TBL] [Abstract][Full Text] [Related]
76. From bench to bedside: the history and progress of CAR T cell therapy.
Mitra A; Barua A; Huang L; Ganguly S; Feng Q; He B
Front Immunol; 2023; 14():1188049. PubMed ID: 37256141
[TBL] [Abstract][Full Text] [Related]
77. Cas12a/Cpf1 knock-in mice enable efficient multiplexed immune cell engineering.
Dong MB; Tang K; Zhou X; Shen J; Chen K; Kim HR; Zhou J; Cao H; Vandenbulcke E; Zhang Y; Chow RD; Du A; Suzuki K; Fang SY; Majety M; Dai X; Chen S
bioRxiv; 2023 Mar; ():. PubMed ID: 36993642
[TBL] [Abstract][Full Text] [Related]
78. CTLA-4 tail fusion enhances CAR-T anti-tumor immunity.
Zhou X; Cao H; Fang SY; Chow RD; Tang K; Majety M; Bai M; Dong MB; Renauer PA; Shang X; Suzuki K; Levchenko A; Chen S
bioRxiv; 2023 Mar; ():. PubMed ID: 36993364
[TBL] [Abstract][Full Text] [Related]
79. Ultralow-dose binary oncolytic/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies.
Wang D; Porter CE; Lim B; Rosewell Shaw A; Robertson CS; Woods ML; Xu Y; Biegert GGW; Morita D; Wang T; Grilley BJ; Heslop H; Brenner MK; Suzuki M
Sci Adv; 2023 Mar; 9(13):eade6790. PubMed ID: 36989357
[TBL] [Abstract][Full Text] [Related]
80. Transmembrane signaling by a synthetic receptor in artificial cells.
Søgaard AB; Pedersen AB; Løvschall KB; Monge P; Jakobsen JH; Džabbarova L; Nielsen LF; Stevanovic S; Walther R; Zelikin AN
Nat Commun; 2023 Mar; 14(1):1646. PubMed ID: 36964156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
